<SEC-DOCUMENT>0001157523-23-000509.txt : 20230403
<SEC-HEADER>0001157523-23-000509.hdr.sgml : 20230403
<ACCEPTANCE-DATETIME>20230403160134
ACCESSION NUMBER:		0001157523-23-000509
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230403
FILED AS OF DATE:		20230403
DATE AS OF CHANGE:		20230403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Legend Biotech Corp
		CENTRAL INDEX KEY:			0001801198
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39307
		FILM NUMBER:		23792548

	BUSINESS ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
		BUSINESS PHONE:		732-317-5050

	MAIL ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a53373375.htm
<DESCRIPTION>LEGEND BIOTECH 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div> <font style="font-family: 'Times New Roman',Times,serif;"> </font>
      <div>
        <div>
          <div style="font-family: 'Times New Roman',Times,serif;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 100%; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div><br>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="font-family: 'Times New Roman',Times,serif;">
            <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">&#160; <br>
          </div>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div>
          <div style="font-family: 'Times New Roman',Times,serif;">&#160; <br>
          </div>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div>
          <div style="font-family: 'Times New Roman',Times,serif;">&#160; <br>
          </div>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Report of Foreign Private Issuer</div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">of the Securities Exchange Act of 1934</div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
        <div style="text-align: center; font-weight: bold;">Date of Report: April 3, 2023<br>
        </div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
        <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39307</div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">Legend Biotech Corporation</div>
        <div style="text-align: center; font-weight: bold;">(Exact Name of Registrant as Specified in its Charter)</div>
        <div style="text-align: center; font-weight: bold;"> <br>
        </div>
        <div style="font-family: 'Times New Roman',Times,serif;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">&#160;<br>
        </div>
        <div style="text-align: center; font-weight: bold;">2101 Cottontail Lane</div>
        <div style="text-align: center; font-weight: bold;">Somerset, New Jersey 08873</div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(Address of principal executive office)</div>
        <div style="font-family: 'Times New Roman',Times,serif;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div style="font-family: 'Times New Roman',Times,serif;"><br>
        </div>
        <div style="text-indent: 36pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
        <div style="text-align: center;">Form 20-F&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 40-F&#160;&#160;&#9744;</div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
        <div style="text-indent: 36pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160;&#160;&#9744;</div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
        <div style="text-indent: 36pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160;&#160;&#9744;</div>
        <div style="text-indent: 36pt;"> <br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: center; font-weight: bold;">
          <div style="font-weight: bold;">
            <div style="font-family: 'Times New Roman',Times,serif;">Legend Biotech Announces Establishment of Strategic Advisory Board</div>
          </div>
          <div style="font-weight: normal;">
            <div><br>
            </div>
          </div>
          <div>
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: normal;">On April 03, 2023<font style="font-family: 'Times New Roman', Times, serif;">, Legend Biotech Corporation (&#8220;</font><font style="font-weight: bold;">Legend Biotech</font><font style="font-family: 'Times New Roman', Times, serif;">&#8221;) issued a press release announcing the establishment of a strategic advisory board, which is attached to this Form 6-K as Exhibit 99.1.</font></div>
            <div style="font-weight: normal;"><br>
            </div>
          </div>
          <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: normal;">This report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference in the registration statements of Legend Biotech on
            Form F-3 (Nos. 333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.</div>
          <div style="text-align: left;"> <br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <u>EXHIBIT INDEX</u></div>
        <div style="font-family: 'Times New Roman',Times,serif;"><br>
        </div>
        <div><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exhibit</font><font style="text-indent: 0px; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-weight: bold; font-family: 'Times New Roman',Times,serif;">Title</font></div>
        <div style="font-family: 'Times New Roman',Times,serif;"><br>
        </div>
        <div><a href="a53373375ex99_1.htm">99.1</a><font style="text-indent: 0px; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: 'Times New Roman',Times,serif;"><a href="a53373375ex99_1.htm">Press Release, dated April 3, 2023</a><br>
          </font></div>
      </div>
      <div> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div>
        <div style="text-align: center;"><font style="font-weight: bold;">SIGNATURES</font> </div>
        <div>&#160;</div>
        <div style="text-indent: 24.5pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div style="font-weight: bold;">&#160;</div>
              </td>
              <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="2">
                <div style="font-weight: bold;">LEGEND BIOTECH CORPORATION</div>
              </td>
              <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div>&#160;</div>
              </td>
              <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div>&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div>&#160;</div>
              </td>
              <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
                <div>Date: April 3, 2023<br>
                </div>
              </td>
              <td style="width: 8%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
                <div>By:</div>
              </td>
              <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
                <div>/s/ Ying Huang</div>
              </td>
              <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div>&#160;</div>
              </td>
              <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div>Name:</div>
              </td>
              <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div>Ying Huang, Ph.D.</div>
              </td>
              <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div>&#160;</div>
              </td>
              <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div>Title:</div>
              </td>
              <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div>Chief Executive Officer</div>
              </td>
              <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
            </tr>

        </table>
        <div><br>
        </div>
      </div>
      <font style="font-family: 'Times New Roman',Times,serif;"> </font> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a53373375ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Legend Biotech Establishes Strategic Advisory Board</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>SOMERSET, N.J.--(BUSINESS WIRE)--April 3, 2023--Legend Biotech Corporation (&#8220;Legend Biotech&#8221; or the &#8220;Company&#8221;) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat
            life-threatening diseases, today announced the formation of a strategic advisory board and the appointments of Michel Vounatsos, former CEO of Biogen Inc., and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, as advisors. Mr.
            Vounatsos and Dr. Maraganore will work closely with Legend Biotech&#8217;s leadership team and Board of Directors to advise on strategic initiatives to advance the Company&#8217;s cell therapy platforms. </p>
          <p> &#8220;We are honored to be joined by such accomplished industry executives, and we welcome Mr. Vounatsos and Dr. Maraganore to our advisory board. We look forward to drawing upon their unique global perspectives and combined experience to help
            drive the company&#8217;s long-term growth objectives,&#8221; said Ying Huang, Legend Biotech&#8217;s CEO. </p>
          <p> <b>About Michel Vounatsos</b> </p>
          <p> Mr. Vounatsos served as Chief Executive Officer and as a member of the Board of Directors of Biogen Inc. from January 2017 to November 2022, shortly after joining the company as Executive Vice President, Chief Commercial Officer in April
            2016. </p>
          <p> Prior to joining Biogen, Mr. Vounatsos spent twenty years at Merck &amp; Co., Inc., where he held a number of leadership roles in strategy, commercial operations and business development. Most recently, he served as President, Primary Care
            and Merck Customer Centricity, where he led the company&#8217;s global primary care business. While at Merck, Mr. Vounatsos also served as President of MSD China and held several commercial leadership positions across Europe. Prior to joining Merck,
            Mr. Vounatsos held management positions at Ciba-Geigy, a Swiss pharmaceuticals company that eventually formed Novartis through its merger with Sandoz Inc. </p>
          <p> Mr. Vounatsos currently serves on the Board of PerkinElmer, Inc., where he is a member of the Audit Committee (March 2020-Present) and Chair of the Nominating and Corporate Governance Committee (Oct.2022-Present). Mr. Vounatsos also serves on
            the Board of Zai Lab (Jan 2023-Present), where he is Chair of the Commercial Committee and member of the Research and Development Committee. In addition, he is on the Advisory Board of Tsinghua University School of Pharmaceutical Sciences, and
            Chair of Supervisory Board of LIRYC, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux. </p>
          <p> Mr. Vounatsos obtained his C.S.C.T. certificate in Medicine from Universit&#233; Victor Segalen, Bordeaux II, France, and an MBA from HEC School of Management in Paris. </p>
          <p> <b>About John Maraganore, PhD</b> </p>
          <p> Dr. Maraganore served as the founding CEO and Director of Alnylam Pharmaceuticals from 2002-2021, where he led the company through the approval and global commercialization of the first four RNA interference therapeutic medicines. At Alnylam,
            he developed the company&#8217;s value strategy, building over $25 billion in market capitalization throughout his tenure. He remains a member of the Alnylam Scientific Advisory Board. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> Prior to joining Alnylam, Dr. Maraganore held a number of leadership roles at Millennium Pharmaceuticals, Inc., across M&amp;A, strategy, and was responsible for the company&#8217;s oncology, and cardiovascular, inflammatory and metabolic diseases
            businesses. Before Millennium, Dr. Maraganore spent ten years at Biogen, Inc. in a number of business and clinical roles, where he led the discovery and development of ANGIOMAX&#174; (bivalirudin). Prior to that, he was a scientist at ZymoGenetics,
            Inc. and the Upjohn Company. </p>
          <p> Currently, Dr. Maraganore serves as a Venture Partner at Arch Venture Partners, a Venture Advisor at Atlas Ventures, a Senior Advisor at Blackstone Life Sciences, Executive Partner at RTW Investments, and as an Advisor at M28. He is Chair
            Emeritus of the Biotechnology Innovation Organization (BIO) and a member of the BIO board and its Executive Committee. In addition, he serves on the board of a number of public and private companies: Agios Pharmaceuticals, Beam Therapeutics,
            Kymera Therapeutics, ProKidney Corp, Takeda Pharmaceuticals; Aera Therapeutics (Chair), Aerium Therapeutics, Aitia (Chair), Hemab Therapeutics (Chair), Orbital Therapeutics (Founder and Executive Chair), and Versanis Bio. </p>
          <p> Dr. Maraganore is actively involved with a number of non-profit organizations committed to the development of future life sciences leaders and to the advancement of innovative medicines for patients. He serves on the Board of the Termeer
            Foundation, Nucleate, CHDI Foundation, the Advisory Board of n-Lorem and Ariadne Labs, and is a member of the MGH Research Institute Advisory Council. </p>
          <p> Dr. Maraganore received his BA, MS, and Ph.D. in biochemistry and molecular biology from the University of Chicago. </p>
          <p> <b>About Legend Biotech</b> </p>
          <p> Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology
            platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&amp;D sites around the world, we apply these innovative technologies to pursue the discovery of
            cutting-edge therapeutics for patients worldwide. </p>
          <p> Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Investor Contacts: </b><br>
            Joanne Choi, Senior Manager, Investor Relations, Legend Biotech <br>
            joanne.choi@legendbiotech.com<br>
            <br>
            Crystal Chen, Manager, Investor Relations, Legend Biotech <br>
            crystal.chen@legendbiotech.com<br>
            <br>
            <b>Press Contact: </b><br>
            Tina Carter, Corporate Communications Lead, Legend Biotech <br>
            tina.carter@legendbiotech.com<br>
            (908) 331-5025 </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
